The role of the tachykinin NK$_1$ receptor in airway changes in a mouse model of allergic asthma

Katelijne O. De Swert, MSc, Kurt G. Tournoy, MD, PhD, Guy F. Joos, MD, PhD, and Romain A. Pauwels, MD, PhD *Ghent, Belgium*

Background: Tachykinins are present in sensory nerves and in nonneuronal cells like macrophages. Human data suggest a role for these peptides in asthma, but the exact role of tachykinins and their receptors in allergic airway inflammation is still a matter of debate.
Objective: The aim of this study was to determine the role of the tachykinin NK$_1$ receptor in allergic airway responses in a mouse model.
Methods: Tachykinin NK$_1$ receptor wild-type and knockout animals were sensitized intraperitoneally to ovalbumin and subsequently exposed from days 14 to 21 to aerosolized ovalbumin (1%). On day 22, the immunologic and histologic changes were evaluated, and lung function measurements were performed.
Results: Mice lacking the tachykinin NK$_1$ receptor and their wild-type litter mates developed inflammatory cell infiltrates in the airways and ovalbumin-specific IgE on sensitization and exposure to ovalbumin compared with saline-exposed controls. No differences were detected between wild-type and knockout mice. The substance P content of alveolar macrophages was not influenced by ovalbumin or by the lack of the NK$_1$ receptor. Ovalbumin-induced hyperresponsiveness was not observed, but at baseline, the knockout mice were more reactive despite similar morphology. Ovalbumin induced more goblet cell hyperplasia in wild-type animals compared with knockout animals. No differences in airway wall thickness were observed.
Conclusion: These data suggest that tachykinin NK$_1$ receptors do not affect allergic airway inflammation or endogenous substance P content of alveolar macrophages but influence baseline responsiveness and promote features of remodeling such as goblet cell hyperplasia. (J Allergy Clin Immunol 2004;113:1093-9.)

Key words: Substance P, hyperplasia, goblet cells, knockout mice

The tachykinins, substance P, and neurokinin A are present in sensory afferent nerves and inflammatory cells in the airways. They may be released by a variety of

Mechanisms of asthma and allergic inflammation

> *Abbreviations used*
> Ao: Area defined by the adventitial perimeter
> Abm: Area defined by the basement membrane
> BAL: Bronchoalveolar lavage
> Pbm: Length of basement membrane
> UK: United Kingdom
> WT: Wild-type

stimuli (eg, allergen, ozone) and have various effects including smooth muscle contraction; facilitation of cholinergic neurotransmission; submucosal gland secretion; vasodilatation; increase in vascular permeability; stimulation of mast cells, B and T lymphocytes, and macrophages; chemoattraction of eosinophils and neutrophils; and the vascular adhesion of neutrophils.[1]

Tachykinins mediate their effects by stimulation of tachykinin NK$_1$, NK$_2$ and NK$_3$ receptors.[2] NK$_1$ receptors are mainly involved in neurogenic inflammation (microvascular leakage and mucus secretion), whereas NK$_2$ receptors are considered to be important in airway smooth muscle contraction. NK$_3$ receptors have not been detected in the airways yet, despite emerging functional evidence for a role in inflammation and responsiveness.

Several lines of evidence indicate a role for tachykinins in airway diseases such as asthma. Elevated levels of tachykinins have been recovered from the airways of patients with asthma, and airway inflammation leads to an upregulation of tachykinin NK$_1$ and NK$_2$ receptors.[1] In guinea pigs, the tachykinin NK$_1$ receptor is involved in both the antigen-induced airway hyperresponsiveness to histamine and the infiltration of inflammatory cells.[3] Substance P also exerts several proinflammatory actions on macrophages[4-7]; even an autocrine function of this peptide has been suggested.[8] Because alveolar macrophages can be considered the first line of defense against inhaled particular matter and microorganisms, this effect may also contribute to the pathology of asthma.

However, from animal studies, there is still debate about the precise role of the tachykinin NK$_1$ receptor in allergic inflammation. An involvement of the tachykinin NK$_1$ receptor in allergic airway inflammation could not been detected in the Brown Norway rat model,[9] and other studies in guinea pigs demonstrated no influence of the tachykinin NK$_1$ receptor on antigen-induced airway eosinophilia[10] and cell influx in bronchoalveolar lavage (BAL).[11]

1093

Therefore, the aim of our study was to point out the role of the tachykinin NK_1 receptor in antigen-induced airway inflammation, responsiveness, and structural changes by using tachykinin NK_1 receptor knockout mice, which is, compared with antagonist studies, a strong model to evaluate involvement of receptors. Furthermore, we wanted to evaluate the role of the NK_1 receptor in controlling the endogenous substance P production of alveolar macrophages during inflammatory stress.

METHODS

Mice

Tachykinin NK_1 receptor knockout and wild-type (WT) mice were derived as described from the mating of heterozygous tachykinin NK_1 receptor mice.[12] The tachykinin NK_1 receptor knockout and WT breeding pairs were provided by the lab of S. Hunt (Cambridge, United Kingdom [UK]). The animals were bred locally and maintained under germ-free conditions in a conventional animal house in the animal research facilities of the Faculty of Medicine and Health Sciences, Ghent University Hospital, and received food and water ad libitum.

Immunization and exposure of mice

On day 0, all mice where actively immunized with ovalbumin (grade III; Sigma Chemical Co, Poole, UK) by intraperitoneal injection of 10 μg ovalbumin, adsorbed to 1 mg $Al(OH)_3$. From days 14 to 21, the mice were exposed daily to PBS or ovalbumin aerosols (1%) for 30 minutes as previously described.[13]

Airway responsiveness

Airway responsiveness to carbachol was measured 24 hours after the final allergen exposure. The mice were anesthetized with pentobarbital (100 mg/kg intraperitoneally; Sanofi, Libourne, France), and a tracheal cannula was inserted. The femoral artery and the jugular vein were cannulated. The animals were placed on a 37°C heated blanket and ventilated with a Harvard Apparatus mouse ventilator, model 687 (Holliston, Mass) at 130 strokes/min (stroke volume, 0.5 mL). Neuromuscular blockade was induced by injecting pancuronium bromide (1 mg/kg) intravenously (Organon; Teknika N.V., Turnhout, Belgium). Lung resistance was calculated from the differential pressure between the airways and the pleural cavity, tidal volume, and flow. These parameters were measured with a computerized pulmonary mechanics analyzer (Mumed lung function recording system, version 5.0, 1999; Mumed Systems, London, UK). Increasing doses of carbachol were administered intravenously (microinfusion pump: 5, 10, 20, 40, 80 μg/kg). Between each dose, the lung resistance was allowed to return to baseline level. The concentration of carbachol causing a 50% increase of baseline resistance (PC_{50} value) was calculated by log-linear interpolation of the dose-response curve. To evaluate the possible role of the tachykinin NK_1 receptor in airway responsiveness through vagal effects, mice were vagotomized before lung function measurements. Both cervical vagal nerves were dissected free and cut. A piece was resected for histologic evaluation. Control mice were sham-operated. During pilot experiments, heart frequency was evaluated before and after vagotomy. An increased heart frequency was observed in vagotomized animals. The effect of exogenous administered substance P (Bachem, Bubendorf, Switzerland) on carbachol-induced contractions was evaluated (protocol adapted from Folkerts et al[14]). On the basis of the dose-response curve, a dose of carbachol was selected that caused approximately 80% of the maximal response in WT animals. Bronchoconstriction was repeated at 10-minute intervals. The first response was variable, but thereafter,

reproducible constrictions could be achieved. After 2 responses to carbachol (80 μg/kg), substance P (40 μg/kg) was injected together with carbachol.

Bronchoalveolar lavage

Immediately after the assessment of airway responsiveness, lungs were lavaged as previously described.[13] A total cell count was performed in a Bürker chamber, and the differential cell counts on at least 400 cells were performed on cytocentrifuged preparations (Cytospin 2; Shandon, Runcorn, UK) by using standard morphologic criteria after staining with May-Grünwald-Giemsa. Cell amounts were expressed as amounts present in the complete lavage sample.

Measurement of ovalbumin specific serum IgE

At the end of the experiment, blood was drawn from the heart for measurement of ovalbumin specific serum IgE. IgE levels were determined as previously described.[13]

Substance P content of bronchoalveolar macrophages

The remaining bronchoalveolar lavage cells (per mouse for ovalbumin-exposed animals; pooled for PBS-exposed or naive animals) were plated in plastic petri dishes pretreated with human and normal goat serum (Gibco BRL, Merelbeke, Belgium) and allowed to adhere for 2 hours at 37°C in a humidified atmosphere containing 5% carbon dioxide. Nonadherent cells were removed by washing monolayers with PBS, and the adherent cells were collected. The macrophages were purified by cell sorting on a FACSvantage flow cytometer (Becton Dickinson, Mountain View, Calif) by using the autofluorescent capacity of these cells. To ensure that the isolated cells were macrophages, cytospin preparations were made and stained with May-Grünwald-Giemsa. The sorted cells were at least 99% macrophages on the basis of morphologic criteria. The macrophages were immediately lysed by resuspending 100,000 cells in 50 μL 2 N acetic acid. The amount of substance P in the lysates was measured in duplicate with the use of a sensitive (20 pg/mL detection limit) competitive peptide enzyme immunoassay (Bachem-Peninsula, San Carlos, Calif) as prescribed by the manufacturer. The assay is specific for substance P with minimal (<0.01%) cross-reactivity for neurokinin A. The concentration of SP in the lysates was used to calculate the amount of SP (pg)/10^6 lysed cells.

Histologic and morphometric analysis

The lungs were infused via the trachea with 4% paraformaldehyde. After excision, the lungs were immersed in fresh fixative overnight. Pieces from all lung lobes were embedded in paraffin and cut in 2-μm−thick sections. Histologic analyses were performed on sections stained with periodic acid-Schiff, Congo red (0.5% in 50% ethanol), or eosin/hematoxylin, respectively. In the stained tissue sections, airways cut in a reasonable cross-section (defined by a ratio of maximal internal diameter to minimal internal diameter <1.8) and with a length of basement membrane (Pbm) >800 μm were examined by light microscopy at magnification 200×. A camera sampled the image of each airway and quantitative measurements were performed on the digital representation of the airways via a computerized image analysis system (KS400; Zeiss, Oberkochen, Germany). The morphometrical parameters[15] that were marked manually on the digital representation of the airway were as follows: Pbm, the area defined by the basement membrane (Abm), and the area defined by the total adventitial perimeter (Ao). The total bronchial wall area (WAt) was calculated from these values (WAt = Ao − Abm), and WAt was normalized to the square length of the basement membrane

(WAt/Pbm^2). Airway morphometry was measured in hematoxylin and eosin stained sections. Goblet cells were quantified in periodic acid-Schiff stained sections. Results were expressed as number of goblet cells per millimeter basement membrane. Peribronchial infiltration with eosinophils was evaluated in lung sections stained with Congo red and expressed as total number of eosinophils per square millimeter WAt.

Statistical analysis

All results are reported as means ±SEMs. Dose-response curves were compared through univariate ANOVA. Post hoc analysis (least significant difference or Scheffé) for groups was performed when ANOVA test was significant. Bronchoconstriction in the presence or absence of substance P was compared with a paired samples t test. Data of quantitative measurements in the airway wall of different mice were pooled together. Mean values of different groups were compared through the Kruskal-Wallis test for multiple comparisons. If significance was reached between the groups, pairwise comparisons were made by using a Mann Whitney U test with Bonferroni corrections. Differences were regarded as significant when P values were < .05. The statistical analyses were accomplished with SPSS for Windows 11.0 software (SPSS Inc, Chicago, Ill).

RESULTS
BAL fluid

Sensitization and subsequent exposure to ovalbumin induced a significant increase in total cell numbers in BAL fluid ($P < .01$; Table I). No differences could be observed between ovalbumin-exposed WT (n = 11) and tachykinin NK$_1$ receptor knockout animals (n = 10). Differential cell counts showed that ovalbumin-exposed groups also had significant increases in percentages of eosinophils ($P < .001$), macrophages ($P < .001$), and lymphocytes and neutrophils ($P < .05$) in their BAL fluid compared with PBS-exposed controls (WT, n = 11; knockout, n = 9; Table I). No differences in eosinophil, macrophage, lymphocyte, and neutrophil numbers were observed between ovalbumin-exposed tachykinin NK$_1$ receptor knockout and ovalbumin-exposed WT mice. A more detailed figure is provided in the Journal's Online Repository (Fig E1; see www.mosby.com/jaci). A possible trend toward a lower number of cells in the knockout mice was not confirmed in additional, independent experiments. Total cell numbers in lavage fluid from naive animals did not differ from each other. Differential cell counts revealed that lavage samples from untreated mice contained nearly 100% macrophages (Table I).

Peribronchial eosinophils

Both tachykinin NK$_1$ receptor WT and knockout animals developed peribronchial eosinophilia on sensitization and exposure to ovalbumin ($P < .001$; Table II). The numbers of infiltrated eosinophils per square millimeter of airway wall were similar in ovalbumin-exposed tachykinin NK$_1$ receptor WT and ovalbumin-exposed tachykinin NK$_1$ receptor knockout mice.

Ovalbumin specific IgE

As proof of active immunization, ovalbumin-specific serum IgE levels were elevated in sensitized mice exposed to ovalbumin compared with those in PBS-exposed animals ($P < .001$ in WT; $P < .01$ in knockout; Table II). No significant difference could be observed between ovalbumin-exposed tachykinin NK$_1$ receptor WT and ovalbumin-exposed tachykinin NK$_1$ receptor knockout mice.

Goblet cells

Ovalbumin exposure induced goblet cell hyperplasia in both tachykinin NK$_1$ receptor WT and knockout animals ($P < .001$ vs PBS-exposed controls; Table II). The amount of goblet cells per millimeter of basement membrane (Pbm) was significantly higher in the ovalbumin-exposed tachykinin NK$_1$ receptor WT mice ($P < .01$ vs ovalbumin-exposed knockout mice; Table II).

Substance P content

No differences in substance P content of bronchoalveolar macrophages could be observed between naive tachykinin NK$_1$ receptor WT and knockout animals (Table III). The influence of ovalbumin sensitization and exposure was also evaluated. No differences could be observed between PBS and ovalbumin-exposed groups or between ovalbumin-exposed tachykinin NK$_1$ receptor WT and ovalbumin-exposed tachykinin NK$_1$ receptor knockout mice (Table III).

Morphometry

No differences in airway wall thickness could be observed between naive tachykinin NK$_1$ receptor WT and knockout animals (Table III). A 1-week allergen exposure did not induce an increase of the airway wall thickness of tachykinin NK$_1$ receptor WT and knockout animals. No differences could be observed between PBS-exposed and ovalbumin-exposed groups or between ovalbumin-exposed tachykinin NK$_1$ receptor WT and ovalbumin-exposed tachykinin NK$_1$ receptor knockout mice (Table III).

Airway responsiveness

Fig 1, A, shows the dose-response curve of the *in vivo* airway responsiveness to intravenous carbachol of naive tachykinin NK$_1$ receptor knockout and WT animals. Tachykinin NK$_1$ receptor knockout mice responded significantly more to carbachol than the tachykinin NK$_1$ receptor WT mice, as demonstrated by a significant leftward shift of the curve and a decreased PC$_{50}$ value ($P < .001$). Vagotomy did not influence the response to carbachol in the naive tachykinin NK$_1$ receptor WT or in the naive tachykinin NK$_1$ receptor knockout mice (Fig 1, B). No shift of the dose-response curve to carbachol or a decrease in PC$_{50}$ value was observed. Vagotomized tachykinin NK$_1$ receptor knockout mice were still more responsive than the WT counterparts. Baseline lung resistance was the same for tachykinin NK$_1$ receptor knockout and WT animals. Exogenous administered

TABLE I. Total and differential cell count in BAL fluid

Group	Total cells ($\times 10^3$)	Macrophages (%)	Eosinophils (%)	Lymphocytes (%)	Neutrophils (%)
WT-naive	91.4±21.1	97.47±0.39	0.1±0.07	1.71±0.51	0.71±0.35
KO-naive	147.5±20.1	97.80±0.62	0.38±0.27	1.58±0.65	0.24±0.07
WT-PBS	190.0±28.5	98.27±1.74	0.31±0.31	1.05±0.29	0.35±0.15
WT-OVA	2492.7±938.6†	50.11±6.90‡	46.1±7.26‡	2.03±0.82	1.82±0.50
KO-PBS	136.3±15.5	98.8±0.33	0.10±0.10	0.93±0.19	0.18±0.10
KO-OVA	767.0±258.4†	58.47±7.87‡	36.00±7.84‡	5.01±1.12*	0.54±0.24

KO, NK$_1$ receptor knockout; *OVA*, ovalbumin.
*$P < .05$.
†$P < .01$.
‡$P < .001$, PBS vs OVA.

TABLE II. Ovalbumin specific serum IgE, peribronchial eosinophils, and goblet cells in epithelium

Group	IgE(U/mL)	Eosinophils (cells/mm^2 airway wall)	Goblet cells (cells/mm Pbm)
WT-PBS	1.95±0.25	41.40±5.01	0.05±0.04
WT-OVA	63.14±12.15†	211.88±25.22†	40.27±4.93†
KO-PBS	1.70±0.49	40.73±5.63	0.03±0.02
KO-OVA	38.16±6.83*	176.50±26.79†	21.76±4.08† ‡

KO, NK$_1$ receptor knockout; *OVA*, ovalbumin.
*$P < .01$.
†$P < .001$, PBS vs OVA.
‡$P < .01$, WT-OVA vs KO-OVA.

TABLE III. Airway wall thickness and substance P content in alveolar macrophages

	Airway wall thickness (WAt/Pbm^2)		Substance P content (pg/100,000 cells)	
Treatment	WT	Knockout	WT	Knockout
Naive	23.2±0.9	24.2±0.8	402±14	405±14
PBS exposure	19.7±0.8	17.7±0.7	462±58	487±26
Ovalbumin exposure	21.4±0.9	21.1±1.4	440±20	450±21

substance P together with carbachol decreased the observed bronchoconstriction to carbachol alone in the tachykinin NK$_1$ receptor WT mice (57.28% ± 13.29% vs 82.24% ± 15.96% increase in lung resistance; n = 8; $P < .01$). This inhibitory effect was not observed in the tachykinin NK$_1$ receptor knockout animals (129.88% ± 25.34% vs 134.60% ± 27.79% increase in lung resistance; n = 8). A 1-week exposure to aerosolized ovalbumin was not able to induce airway hyperresponsiveness to carbachol in the tachykinin NK$_1$ receptor WT and the knockout mice versus the PBS-exposed controls. Neither leftward shift of the dose-response curve nor a decrease in PC$_{50}$ value could be observed in either strain ($P > .05$; Fig 1, *C*). However, PBS-exposed and ovalbumin-exposed tachykinin NK$_1$ receptor knockout mice respond significantly more to carbachol in comparison with the WT counterparts. This is illustrated by a significant leftward shift of the dose-response curve ($P < .01$) to carbachol in the PBS-exposed animals and in the ovalbumin-exposed mice.

DISCUSSION

In our mouse model, no effect of the tachykinin NK$_1$ receptor on the allergic airway inflammation could be observed. Ovalbumin-induced inflammatory cell influxes in BAL fluid and ovalbumin-specific serum IgE levels of tachykinin NK$_1$ receptor knockout mice were similar to those obtained from WT littermates. Also, the peribronchiolar eosinophilia was similar in both groups, suggesting no proinflammatory action of tachykinins through this receptor. These findings corroborate studies in rats and guinea pigs in which the use of tachykinin NK$_1$ receptor antagonists indicated that the tachykinin NK$_1$ receptor is not involved in antigen-induced inflammatory cell influxes in BAL.[9-11] Our results contrast with another study in guinea pigs in which signaling through the tachykinin NK$_1$ receptor augmented the allergen-induced infiltration of eosinophils, neutrophils, and lymphocytes in the airways.[3] Differences according to species specificity and/or methodology may explain these conflicting results. In another mouse model of lung inflammation, a NK$_1$ receptor antagonist reduced significantly the total number of inflammatory cells retrieved by BAL,[16] but this model represented inflammation compartmentalized in lung parenchyma. Several studies using tachykinin NK$_1$ receptor knockout mice suggested a role for this receptor in inflammation in various organs.[1] Bozic et al[17] reported that the disruption of the tachykinin NK$_1$ receptor protected the lung from immune complex injury. Their animal model is also not designed to evaluate allergic airway inflammation and therefore does not contrast with our observations.

A

B

C

FIG 1. A, Airway responsiveness to carbachol in naive NK$_1$ receptor WT *(closed squares)* and NK$_1$ receptor knockout animals *(closed circles).* **B,** Responsiveness to carbachol in vagotomized and sham-operated naive WT *(open* and *closed squares,* respectively) and naive knockout animals *(open* and *closed circles).* **C,** Responsiveness to carbachol in ovalbumin-exposed and PBS-exposed WT *(open* and *closed squares)* and knockout *(open* and *closed circles)* animals.

Because macrophages are the first line of defense, they may play a role in allergic inflammation. An autocrine and autofeedback function (maintaining baseline and increasing endogenous substance P levels on stress) for substance

P in these cells has been suggested.[8,18-20] Pascual and Bost[8] reported that P388D1 macrophages produced substance P and responded to that production in an autocrine or paracrine fashion, leading to release of IL-1—like activity during stress. Lai et al[18] demonstrated that a specific NK$_1$ receptor antagonist abrogated not only the exogenous substance P—induced substance P mRNA expression but also resulted in substance P mRNA expression that was lower than that of baseline control, suggesting that endogenously produced substance P controlled its own mRNA expression. Therefore, we hypothesized that the lack of the receptor might influence the endogenous substance P levels of alveolar macrophages. However, no differences in endogenous substance P levels of these cells from NK$_1$ receptor WT and knockout animals were observed, suggesting no autofeedback mechanism in these conditions. Furthermore, if substance P and its receptor were involved in an autocrine loop to release proinflammatory cytokines on inflammation, as suggested by Pascual and Bost, [8] we expected to observe higher substance P levels in alveolar macrophages of allergic WT animals compared with controls, because signaling through the receptor would also activate the autofeedback system. Although higher numbers of alveolar macrophages were retrieved from lungs of ovalbumin-treated animals, no alterations of endogenous substance P levels from macrophages from PBS-exposed and ovalbumin-exposed WT mice were observed. These data suggest that the endogenous substance P levels are not upregulated and probably not involved in the augmentation of cytokine release in this model of allergic inflammation. However, the activation status of the macrophages of ovalbumin-exposed WT and knockout animals may be different, as was suggested by an *in vitro* study in which release of endogenous substance P altered the activation status of P388D1 macrophages.[8] If this is the case, nevertheless, no differences in inflammation are induced by the altered activation status. Furthermore, antagonizing the NK$_1$ receptor has no influence on the increased activation status of alveolar macrophages after ovalbumin challenge in sensitized guinea pigs, suggesting no effect of the NK$_1$ receptor on the activation of macrophages in ovalbumin-sensitized and ovalbumin-exposed animals.[11]

We did not observe any induced hyperresponsiveness in our model, although others did report allergen-induced hyperresponsiveness in mice,[21,22] guinea pigs,[23,24] and rats.[25] Therefore, no conclusions about the role of the NK$_1$ receptor in allergen-induced hyperresponsiveness could be made. This conflicting result may be related to the marked variation among the used models with respect to the background strains of the animals,[26-28] the variety of sensitization and challenge protocols used, and the different readouts used to assess the airway responsiveness.[29,30] It is of interest to note that in naive animals lacking the tachykinin NK$_1$ receptor, an increased responsiveness to intravenous carbachol was observed. This observation corroborates the fact that mice with a targeted deletion of the tachykinin I gene (mice lacking

substance P) are hyperresponsive to intravenous methacholine.[31] Hyperresponsiveness must be a function of excessive airway narrowing. Possible mechanisms responsible for this excessive narrowing include altered neural pathways, remodeling of the airways, and the presence of inflammatory mediators.[32] In this particular case, the effect of inflammatory mediators can be neglected, because in naive animals, no inflammation was observed. Moreover, no altered airway morphology was observed. The thickness of the airway wall was similar in tachykinin NK_1 receptor WT and knockout animals. The dominant neural control of the airway smooth muscle is provided by the parasympathetic fibers of the vagus nerves. The tachykinin NK_1 receptor may be involved in central vagal control.[10,33] However, cutting of these vagus nerves had no effect on the observed responsiveness in the naive NK_1 receptor knockout animals or in the WT mice. This means that central neural elements do not influence the observed response to carbachol. Altered smooth muscle contractility to carbachol in the NK_1 receptor knockout animals does not seem to be the cause, either.[34] On sensory nerve activation (through contraction), an antidromic release of tachykinins from c-fibers via an axon reflex may occur. These peptides may in turn mediate a relaxation through binding with the epithelium and subsequent release of prostaglandin, as was described *in vitro*.[34] Exogenous substance P indeed has an inhibitory effect on carbachol-induced bronchoconstriction in NK_1 receptor WT mice. This inhibition was abolished in the NK_1 receptor knockout mice, suggesting that this protective effect is mediated through the NK_1 receptor. Exposure to ovalbumin increased the numbers of goblet cells in both WT and knockout animals, but the amount of goblet cells per millimeter of basement membrane was significantly less in the knockout mice, suggesting a role for the NK_1 receptor in goblet cell hyperplasia. Increased numbers of goblet cells are considered part of airway remodeling in asthma.[35] The hyperplasia is linked with increased mucus secretion and consequent airflow obstruction, an important feature of asthma. The mechanisms underlying the development of goblet cell hyperplasia are now being unraveled, mainly through the use of murine asthma models. Several mechanisms may explain our findings. First, inhaled allergens induce a T_H2 lymphocyte response with release of cytokines that induce goblet cell hyperplasia either directly or indirectly.[36] As substance P[37] and its receptor[38,39] are expressed in and on lymphocytes, these cells may be influenced in an autocrine or paracrine fashion to augment the release of these cytokines. Several studies have already shown that substance P is able to modulate the chemotaxis, proliferation, and activation of lymphocytes.[40] Second, substance P may influence the goblet cell hyperplasia by a direct effect on tachykinin NK_1 receptors on the epithelium. The peptide may be released by a variety of stimuli and stimulate goblet cells to proliferate. Substance P is present in nerve profiles, found beneath and within the epithelium and around submucosal glands.[41,42]

Furthermore, Chu et al[43] demonstrated that epithelial cells are an additional source of substance P. They also demonstrated expression of the tachykinin NK_1 receptor on goblet cells. Further evidence for this hypothesis is provided by their work demonstrating increased expression of substance P and its receptor in asthmatics, which was correlated with the mucus content in the airway epithelium.[43] In conclusion, the tachykinin NK_1 receptor is involved in the secretory response of goblet cells,[44-48] and we provide evidence for an involvement of this receptor in proliferation of these cells induced by antigen.

To conclude, we can state that despite the fact that the tachykinin NK_1 receptor is not involved in the antigen-induced airway inflammation, it does augment the antigen-induced goblet cell hyperplasia in a mouse model of allergic asthma. This may have important implications for the use of specific NK_1 receptor antagonists in pathologies like asthma, in which goblet cell hyperplasia and mucus hypersecretion are important features.

REFERENCES

1. Joos GF, De Swert KO, Pauwels RA. Airway inflammation and tachykinins: prospects for the development of tachykinin receptor antagonists. Eur J Pharmacol 2001;429:239-50.
2. Maggi CA. The troubled story of tachykinins and neurokinins. Trends Pharmacol Sci 2000;21:173-5.
3. Schuiling M, Zuidhof AB, Zaagsma J, Meurs H. Involvement of tachykinin NK1 receptor in the development of allergen-induced airway hyperreactivity and airway inflammation in conscious, unrestrained guinea pigs. Am J Respir Crit Care Med 1999;159:423-30.
4. Lotz M, Vaughan JH, Carson DA. Effect of neuropeptides on production of inflammatory cytokines by human monocytes. Science 1988;241:1218-21.
5. Murris Espin M, Pinelli E, Pipy B, Leophonte P, Didier A. Substance P and alveolar macrophages: effects on oxidative metabolism and eicosanoid production. Allergy 1995;50:334-9.
6. Kimball ES, Persico FJ, Vaught JL. Substance P, neurokinin A, and neurokinin B induce generation of IL-1-like activity in P388D1 cells. J Immunol 1988;141:3564-9.
7. Ho WZ, Stavropoulos G, Lai JP, Hu BF, Magafa V, Anagnostides S, et al. Substance P C-terminal octapeptide analogues augment tumor necrosis factor-alpha release by human blood monocytes and macrophages. J Neuroimmunol 1998;82:126-32.
8. Pascual DW, Bost KL. Substance P production by P388D1 macrophages: a possible autocrine function for this neuropeptide. Immunology 1990;71:52-6.
9. Maghni K, Taha R, Afif W, Hamid Q, Martin JG. Dichotomy between neurokinin receptor actions in modulating allergic airway responses in an animal model of helper T cell type 2 cytokine-associated inflammation. Am J Respir Crit Care Med 2000;162:1068-74.
10. Costello RW, Fryer AD, Belmonte KE, Jacoby DB. Effects of tachykinin NK1 receptor antagonists on vagal hyperreactivity and neuronal M2 muscarinic receptor function in antigen challenged guinea-pigs. Br J Pharmacol 1998;124:267-76.
11. Boichot E, Germain N, Emonds Alt X, Advenier C, Lagente V. Effects of SR 140333 and SR 48968 on antigen and substance P-induced activation of guinea-pig alveolar macrophages. Clin Exp Allergy 1998;28:1299-305.

12. De Felipe C, Herrero JF, O'Brien JA, Palmer JA, Doyle CA, Smith AJ, et al. Altered nociception, analgesia and aggression in mice lacking the receptor for substance P. Nature 1998;392:394-7.

13. Tournoy KG, Kips JC, Pauwels RA. Counterbalancing of TH2-driven allergic airway inflammation by IL-12 does not require IL-10. J Allergy Clin Immunol 2001;107:483-91.

14. Folkerts G, Heuven-Nolsen D, Nijkamp FP. Bradykinin causes inhibition of methacholine-induced bronchoconstriction in vivo in mice. Naunyn Schmiedebergs Arch Pharmacol 2001;364:53-8.

15. Bai A, Eidelman DH, Hogg JC, James AL, Lambert RK, Ludwig MS, et al. Proposed nomenclature for quantifying subdivisions of the bronchial wall. J Appl Physiol 1994;77:1011-4.

16. Kaltreider HB, Ichikawa S, Byrd PK, Ingram DA, Kishiyama JL, Sreedharan SP, et al. Upregulation of neuropeptides and neuropeptide receptors in a murine model of immune inflammation in lung parenchyma. Am J Respir Cell Mol Biol 1997;16:133-44.

17. Bozic CR, Lu B, Hopken UE, Gerard C, Gerard NP. Neurogenic amplification of immune complex inflammation. Science 1996;273:1722-5.

18. Lai JP, Ho WZ, Yang JH, Wang X, Song L, Douglas SD. A non-peptide substance P antagonist down-regulates SP mRNA expression in human mononuclear phagocytes. J Neuroimmunol 2002;128:101-8.

19. Bost KL, Breeding SA, Pascual DW. Modulation of the mRNAs encoding substance P and its receptor in rat macrophages by LPS. Reg Immunol 1992;4:105-12.

20. Germonpre PR, Bullock GR, Lambrecht BN, Van De Velde V, Luyten WH, Joos GF, et al. Presence of substance P and neurokinin 1 receptors in human sputum macrophages and U-937 cells. Eur Respir J 1999;14:776-82.

21. Braun A, Appel E, Baruch R, Herz U, Botchkarev V, Paus R, et al. Role of nerve growth factor in a mouse model of allergic airway inflammation and asthma. Eur J Immunol 1998;28:3240-51.

22. de Bie JJ, Henricks PA, Cruikshank WW, Hofman G, Jonker EH, Nijkamp FP, et al. Modulation of airway hyperresponsiveness and eosinophilia by selective histamine and 5-HT receptor antagonists in a mouse model of allergic asthma. Br J Pharmacol 1998;124:857-64.

23. Advenier C, Lagente V, Boichot E. The role of tachykinin receptor antagonists in the prevention of bronchial hyperresponsiveness, airway inflammation and cough. Eur Respir J 1997;10:1892-906.

24. Boichot E, Biyah K, Germain N, Emonds Alt X, Lagente V, Advenier C. Involvement of tachykinin NK1 and NK2 receptors in substance P-induced microvascular leakage hypersensitivity and airway hyperresponsiveness in guinea-pigs. Eur Respir J 1996;9:1445-50.

25. Palmans E, Kips JC, Pauwels RA. Prolonged allergen exposure induces structural airway changes in sensitized rats. Am J Respir Crit Care Med 2000;161:627-35.

26. Duguet A, Biyah K, Minshall E, Gomes R, Wang CG, Taoudi-Benchekroun M, et al. Bronchial responsiveness among inbred mouse strains: role of airway smooth-muscle shortening velocity. Am J Respir Crit Care Med 2000;161:839-48.

27. Ewart SL, Kuperman D, Schadt E, Tankersley C, Grupe A, Shubitowski DM, et al. Quantitative trait loci controlling allergen-induced airway hyperresponsiveness in inbred mice. Am J Respir Cell Mol Biol 2000;23:537-45.

28. Whitehead GS, Walker JK, Berman KG, Foster WM, Schwartz DA. Allergen-induced airway disease is mouse strain dependent. Am J Physiol Lung Cell Mol Physiol 2003;285:L32-42.

29. Glaab T, Daser A, Braun A, NeuhausSteinmetz U, Fabel H, Alarie Y, et al. Tidal midexpiratory flow as a measure of airway hyperresponsiveness in allergic mice. Am J Physiol 2001;280:L565-73.

30. Hamelmann E, Schwarze J, Takeda K, Oshiba A, Larsen GL, Irvin CG, et al. Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography. Am J Respir Crit Care Med 1997;156:766-75.

31. Tuck SA, Shah S, Martin JG. Airway hyperresponsiveness in mice with targeted deletion of the tachykinin I gene. [abstract]. Am J Respir Crit Care Med 2002;165:A802.

32. Pare PD, Roberts CR, Bai TR, Wiggs BJ. The functional consequences of airway remodeling in asthma. Monaldi Arch Chest Dis 1997;52:589-96.

33. Evans CM, Belmonte KE, Costello RW, Jacoby DB, Gleich GJ, Fryer AD. Substance P-induced airway hyperreactivity is mediated by neuronal M(2) receptor dysfunction. Am J Physiol Lung Cell Mol Physiol 2000;279:L477-86.

34. Tournoy KG, De Swert KO, Leclere PG, Lefebvre RA, Pauwels RA, Joos GF. Modulatory role of tachykinin NK1 receptor in cholinergic contraction of mouse trachea. Eur Respir J 2003;21:3-10.

35. Jeffery PK. Remodeling in asthma and chronic obstructive lung disease. Am J Respir Crit Care Med 2001;164:S28-38.

36. Rogers DF. Airway goblet cell hyperplasia in asthma: hypersecretory and anti-inflammatory? Clin Exp Allergy 2002;32:1124-7.

37. Lai JP, Douglas SD, Ho WZ. Human lymphocytes express substance P and its receptor. J Neuroimmunol 1998;86:80-6.

38. Cook GA, Elliott D, Metwali A, Blum AM, Sandor M, Lynch R, et al. Molecular evidence that granuloma T lymphocytes in murine schistosomiasis mansoni express an authentic substance P (NK-1) receptor. J Immunol 1994;152:1830-5.

39. Payan DG, Brewster DR, Missirian-Bastian A, Goetzl EJ. Substance P recognition by a subset of human T lymphocytes. J Clin Invest 1984;74:1532-9.

40. Joos GF, Germonpre PF, Pauwels RA. Role of tachykinins in asthma. Allergy 2000;55:321-37.

41. Lundberg JM, Hokfelt T, Martling CR, Saria A, Cuello C. Substance P-immunoreactive sensory nerves in the lower respiratory tract of various mammals including man. Cell Tissue Res 1984;235:251-61.

42. Luts A, Uddman R, Alm P, Basterra J, Sundler F. Peptide-containing nerve fibers in human airways: distribution and coexistence pattern. Int Arch Allergy Immunol 1993;101:52-60.

43. Chu HW, Kraft M, Krause JE, Rex MD, Martin RJ. Substance P and its receptor neurokinin 1 expression in asthmatic airways. J Allergy Clin Immunol 2000;106:713-22.

44. Ramnarine SI, Rogers DF. Non-adrenergic, non-cholinergic neural control of mucus secretion in the airways. Pulm Pharmacol 1994;7:19-33.

45. Ramnarine SI, Hirayama Y, Barnes PJ, Rogers DF. "Sensory-efferent" neural control of mucus secretion: characterization using tachykinin receptor antagonists in ferret trachea in vitro. Br J Pharmacol 1994;113:1183-90.

46. Wagner U, Fehmann H, Bredenbroker D, Kluber D, Lange A, Wichert P. Effects of selective tachykinin-receptor antagonists on tachykinin-induced airway mucus secretion in the rat. Neuropeptides 1999;33:55-61.

47. Khan S, Liu YC, Khawaja AM, Manzini S, Rogers DF. Effect of the long-acting tachykinin NK1 receptor antagonist MEN 11467 on tracheal mucus secretion in allergic ferrets. Br J Pharmacol 2001;132:189-96.

48. Phillips JE, Hey JA, Corboz MR. Tachykinin NK(3) and NK(1) receptor activation elicits secretion from porcine airway submucosal glands. Br J Pharmacol 2003;138:254-60.